News

:::
:::

NHRI scientists harness nanoparticles to improve use of weight loss drug s by reduc ing their side effects

  • Date: 2021-02-22
  • Update: 2021-02-22
  • Source: 國家衛生研究院
  • Views: 99

NHRI scientists
harness nanoparticles to improve use
of weight loss drug s by reduc ing their side effects
─NHRI has established a novel application of MSNs, enhancing the utility and market development of lipase inhibitor-based anti-obesity drugs by reducing their side effects and elevating life quality─
Fe
bru a ry 22, 2021
Obesity is a disease of modern civilization, with obese people comprising 40% of
the global population, according to the World Health Organization (WHO). In
Taiwan, most people work long hours, which can lead to unhealthy living and eating
habits. Obesity c an cause many chronic diseases, such as cardiovascular disease,
diabetes, and other life threatening ailments. Therefore, weight control has become
one of the world’s most urgent health issues.
Orlistat is the main active ingredient in many weight
contr ol drugs. Diet pills that
contain Orlistat have an overall market share of over 75% of what was projected to
be a multi billion dollar sector in 2019, according to a 2017 GBI study. Orlistat acts
as a lipase inhibitor to reduce the degradation and in vivo absorption of
gastrointestinal fats, resulting in excess fat being excreted from the large intestine.
However, in the anti obesity market, the use of weight controlling drugs that reduce
fat absorption, such as Xenical, is often associated with some unp leasant side effects,
such as diarrhea and steatorrhea/oily stool. In an effort to minimize or eliminate these
unpleasant side effects, drug dosages have been reduced. However, this has led to
much lower effectiveness of the drugs.
Scientists
Scientists atat InstitutInstitute of Biomedical Engineering and Nanomedicine, e of Biomedical Engineering and Nanomedicine, National National Health Research Institutes (NHRI)Health Research Institutes (NHRI) of Taiwanof Taiwan have succeeded in using mesoporous have succeeded in using mesoporous silica nanoparticles (MSNs), a unique nanomaterial, to reduce the side effects of silica nanoparticles (MSNs), a unique nanomaterial, to reduce the side effects of these lipase inhibitorthese lipase inhibitor--based antibased anti--obeobesity drugs. The high surface area (800sity drugs. The high surface area (800--1000 m1000 m22/g) /g) of MSNs potentiates their capability of oil absorption and gelatinization. The silicon of MSNs potentiates their capability of oil absorption and gelatinization. The silicon dioxide that comprises MSNs is also biocompatible, and has been widely utilized in dioxide that comprises MSNs is also biocompatible, and has been widely utilized in food additives and as an antacid agefood additives and as an antacid agent in gastrointestinal medications. Based on the nt in gastrointestinal medications. Based on the above characteristics, MSNs are attractive as a material for combination therapy with above characteristics, MSNs are attractive as a material for combination therapy with Orlistat. Orlistat.
The NHRI researchers developed and used MSNs to reduce the side effects of
The NHRI researchers developed and used MSNs to reduce the side effects of lipase inhibitorlipase inhibitor--based antibased anti--obesitobesity drugs, thereby enhancing the utility and market y drugs, thereby enhancing the utility and market development of these drugsdevelopment of these drugs, and, and greatly improving greatly improving user’s user’s satisfactionsatisfaction and quality of and quality of lifelife..
The key concepts and technologies relevant to this invention are protected by
The key concepts and technologies relevant to this invention are protected by important international patentimportant international patent--protection laws and regulations, including a US patent protection laws and regulations, including a US patent (USPTO No. US9185928 B2 2015/11/17), a PRC patent (CN No 201380066277.8 (USPTO No. US9185928 B2 2015/11/17), a PRC patent (CN No 201380066277.8 2017/06/20), an EU patent (2017/04/11; Registration: UK, Germany, France, Italy, 2017/06/20), an EU patent (2017/04/11; Registration: UK, Germany, France, Italy, and Spain), a Taiwan patent (No I614017, 2017/12and Spain), a Taiwan patent (No I614017, 2017/12/12), an /12), an AustraliaAustralian patent (No n patent (No AU2013361217 A1, 2019), and a Canadian patentAU2013361217 A1, 2019), and a Canadian patent (No 2,895,357, 2019). (No 2,895,357, 2019).
This invention has also gained several awards, including the Future Tech (FUTEX)
This invention has also gained several awards, including the Future Tech (FUTEX) Award (Highlighted Technology, Award (Highlighted Technology, MOSTMOST, Taiwan), Taiwan) in in 20192019, the , the 16th 16th NationalNational Innovation Award in 2019, and the Innovation Award in 2019, and the 17th 17th National Innovation Excelsior Award in National Innovation Excelsior Award in 2020.2020.

Related photos